OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

First Results of the Phase 3 CheckMate 9ER Trial

home / insights / first-results-of-the-phase-3-checkmate-9er-trial

Treatment Landscape of Advanced Renal Cell Carcinoma

EP. 1: Treatment Landscape of Advanced Renal Cell Carcinoma

Toni Choueiri, MD;Sumanta Kumar Pal, MD
October 15th 2020
Data from the CheckMate 9ER Trial for Advanced RCC

EP. 2: Data from the CheckMate 9ER Trial for Advanced RCC

Toni Choueiri, MD;Sumanta Kumar Pal, MD
October 15th 2020
Impact of CheckMate 9ER on the Treatment of Advanced RCC

EP. 3: Impact of CheckMate 9ER on the Treatment of Advanced RCC

Toni Choueiri, MD;Sumanta Kumar Pal, MD
October 15th 2020
Sequencing Therapies for Advanced Renal Cell Carcinoma

EP. 4: Sequencing Therapies for Advanced Renal Cell Carcinoma

Toni Choueiri, MD;Sumanta Kumar Pal, MD
October 15th 2020
Experience Using Cabozantinib And Nivolumab for Advanced RCC

EP. 5: Experience Using Cabozantinib And Nivolumab for Advanced RCC

Toni Choueiri, MD;Sumanta Kumar Pal, MD
October 15th 2020

Latest Conference Coverage

Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS

Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia

Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact